Ajanta Pharma Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Ajanta Pharma kazanç ve gelirin sırasıyla yıllık 16.3% ve 11.2% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 16.3% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 23.7% olacağı tahmin edilmektedir.

Anahtar bilgiler

16.3%

Kazanç büyüme oranı

16.3%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	18.4%
Gelir büyüme oranı	11.2%
Gelecekteki özkaynak getirisi	23.7%
Analist kapsamı	Good
Son güncelleme	29 Oct 2024

Gelecekteki son büyüme güncellemeleri

Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Oct 31

Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next

Aug 04

Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results

May 05

Recent updates

Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Oct 31

Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

Sep 10

We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Aug 23

Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next

Aug 04

Some Confidence Is Lacking In Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E

Aug 01

With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case

Jun 01

Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results

May 05

Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price

Apr 05

We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Feb 23

Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected

Dec 23

Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

Aug 26

These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well

Feb 07

I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut

Feb 06

Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Dec 13

Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50

Oct 31

Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching

Sep 22

Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?

Sep 08

Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?

Aug 26

Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet

Jul 07

Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?

Jun 14

Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?

May 15

Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why

Apr 10

Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?

Mar 11

Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?

Feb 24

The Ajanta Pharma (NSE:AJANTPHARM) Share Price Is Up 56% And Shareholders Are Holding On

Jan 30

What Can We Make Of Ajanta Pharma's (NSE:AJANTPHARM) CEO Compensation?

Jan 18

Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Jan 06

Kazanç ve Gelir Büyüme Tahminleri

NSEI:AJANTPHARM - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
3/31/2027	59,429	13,179	10,903	11,809	7
3/31/2026	52,773	11,131	8,563	9,720	11
3/31/2025	47,273	9,584	7,822	9,381	8
9/30/2024	44,908	8,750	9,127	11,625	N/A
6/30/2024	43,326	8,538	N/A	N/A	N/A
3/31/2024	42,087	8,162	6,327	7,851	N/A
12/31/2023	40,365	7,357	N/A	N/A	N/A
9/30/2023	39,031	6,602	6,610	8,199	N/A
6/30/2023	38,128	6,215	N/A	N/A	N/A
3/31/2023	37,426	5,880	6,176	7,921	N/A
12/31/2022	37,311	6,169	N/A	N/A	N/A
9/30/2022	35,972	6,742	5,027	6,613	N/A
6/30/2022	35,439	7,136	N/A	N/A	N/A
3/31/2022	33,410	7,127	4,129	5,617	N/A
12/31/2021	32,275	7,207	N/A	N/A	N/A
9/30/2021	31,384	7,056	3,607	5,379	N/A
6/30/2021	29,695	6,799	N/A	N/A	N/A
3/31/2021	28,897	6,539	4,047	5,763	N/A
12/31/2020	28,148	6,238	N/A	N/A	N/A
9/30/2020	27,173	5,547	3,593	5,334	N/A
6/30/2020	26,441	5,008	N/A	N/A	N/A
3/31/2020	25,879	4,677	2,174	4,568	N/A
12/31/2019	24,211	4,274	N/A	N/A	N/A
9/30/2019	22,550	3,868	1,451	4,409	N/A
6/30/2019	21,563	3,958	N/A	N/A	N/A
3/31/2019	20,554	3,870	315	3,745	N/A
12/31/2018	20,654	3,926	N/A	N/A	N/A
9/30/2018	21,674	4,731	N/A	N/A	N/A
6/30/2018	21,636	4,796	N/A	N/A	N/A
3/31/2018	21,258	4,686	N/A	2,811	N/A
12/31/2017	20,590	4,882	N/A	N/A	N/A
9/30/2017	20,050	4,833	N/A	N/A	N/A
6/30/2017	19,805	4,821	N/A	N/A	N/A
3/31/2017	19,833	5,068	N/A	6,093	N/A
12/31/2016	19,386	4,908	N/A	N/A	N/A
9/30/2016	18,821	4,622	N/A	N/A	N/A
6/30/2016	18,072	4,350	N/A	N/A	N/A
3/31/2016	17,340	4,156	N/A	3,261	N/A
12/31/2015	16,809	3,692	N/A	N/A	N/A
9/30/2015	16,160	3,510	N/A	N/A	N/A
6/30/2015	15,502	3,340	N/A	N/A	N/A
3/31/2015	14,736	3,099	N/A	2,794	N/A
3/31/2014	12,083	2,339	N/A	2,124	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: AJANTPHARM 'nin tahmini kazanç büyümesi (yıllık 16.3% ) tasarruf oranının ( 6.7% ) üzerindedir.

Kazançlar ve Piyasa: AJANTPHARM şirketinin kazançlarının (yıllık 16.3% ) Indian pazarından (yıllık 17.9% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: AJANTPHARM şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: AJANTPHARM şirketinin gelirinin (yıllık 11.2% ) Indian pazarından (yıllık 10.2% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: AJANTPHARM şirketinin gelirinin (yıllık 11.2% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: AJANTPHARM 'in Özsermaye Getirisi'nin 3 yıl içinde yüksek olması tahmin ediliyor ( 23.7 %)

Ajanta Pharma Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Price target increased by 7.1% to ₹2,874

Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next

Price target increased by 7.6% to ₹2,664

Price target increased by 7.4% to ₹2,440

Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results

Recent updates

Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Ajanta Pharma Limited to Report Q2, 2025 Results on Oct 28, 2024

Price target increased by 7.1% to ₹2,874

Chief Financial Officer recently sold ₹20m worth of stock

Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Executive Vice President recently sold ₹5.9m worth of stock

Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next

Price target increased by 7.6% to ₹2,664

Some Confidence Is Lacking In Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Ajanta Pharma Limited to Report Q1, 2025 Results on Jul 30, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

Ajanta Pharma Limited, Annual General Meeting, Jul 18, 2024

With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case

Price target increased by 7.4% to ₹2,440

Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results

Ajanta Pharma Limited (NSEI:AJANTPHARM) announces an Equity Buyback for 1,028,881 shares, representing 0.82% for INR 2,850 million.

Full year 2024 earnings: EPS exceeds analyst expectations

Ajanta Pharma Limited to Report Q4, 2024 Final Results on May 02, 2024

Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price

We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Ajanta Pharma Limited Approves Second Interim Dividend for the Year Fiscal Year 2024, Payable on or After 19th February 2024

Ajanta Pharma Limited to Report Q3, 2024 Results on Jan 31, 2024

Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected

Price target increased by 7.5% to ₹1,949

Second quarter 2024 earnings: EPS exceeds analyst expectations

Ajanta Pharma Limited to Report Q2, 2024 Results on Oct 31, 2023

Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

Price target increased by 10.0% to ₹1,652

First quarter 2024 earnings released: EPS: ₹16.53 (vs ₹13.63 in 1Q 2023)

Ajanta Pharma Limited to Report Q1, 2024 Results on Jul 27, 2023

Insider recently sold ₹2.1m worth of stock

Ajanta Pharma Limited, Annual General Meeting, Jul 18, 2023

Insider recently sold ₹1.9m worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ajanta Pharma Limited to Report Q3, 2023 Results on Feb 01, 2023

Insufficient new directors

Ajanta Pharma Limited Approves Interim Dividend

Second quarter 2023 earnings: EPS misses analyst expectations

Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

Ajanta Pharma Limited to Report Q2, 2023 Results on Nov 03, 2022

Price target increased to ₹1,574

US FDA Announces Inspection of Pharma Limited Dahej Facility

Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Ajanta Pharma Limited to Report Q1, 2023 Results on Jul 28, 2022

Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ajanta Pharma Limited, Annual General Meeting, Aug 04, 2022

Investor sentiment deteriorated over the past week

Price target decreased to ₹2,335

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ajanta Pharma Limited to Report Q4, 2022 Results on May 10, 2022

A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Insufficient new directors

Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ajanta Pharma Limited (NSEI:AJANTPHARM) announces an Equity Buyback for 1,120,000 shares, representing 1.29% for INR 2,856 million.

Insider recently sold ₹8.1m worth of stock

Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Insider recently sold ₹1.1m worth of stock

Upcoming dividend of ₹9.50 per share

Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50

Second quarter 2022 earnings released: EPS ₹22.64 (vs ₹19.51 in 2Q 2021)